In this study, we provide new insights into the role of ELAVL2 in GBM by investigating the clinical and molecular aspects of ELAVL2 in tumor progression and show that ELAVL2 may act as a potential tumor suppressor by regulating the mRNA stability of downstream effectors, thereby suppressing aggressive MES transformation in GBM. This evidence concerns the gene ELAVL2 and neoplasm.